MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, FBLG had -$3,978K decrease in cash & cash equivalents over the period. -$3,978K in free cash flow.

Cash Flow Overview

Change in Cash
-$3,978K
Free Cash flow
-$3,978K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Change in fair value of warrant liability
0 -
Change in fair value of forward contract liability
0 -
Commitment fee payable
0 -
Payable to parent
0 -
Change in fair value of sepa put option liability
23 -
Change in fair value of convertible debt
-846 -117
Non-cash original discount on convertible debt
625 -
Stock-based compensation expense
704 1,280
Amortization of operating lease right-of-use asset
166 254
Prepaid expenses
-960 1,108
Accounts payable and accrued expenses
-732 -646
Other current assets
0 -18
Other assets
0 48
Operating lease liability
-170 -250
Net loss
-15,402 -
Depreciation expense
65 113
Net cash used in operating activities
-3,972 -9,259
Purchases of property and equipment
6 256
Net cash used in investing activities
-6 -256
Repayments of short-term borrowing
0 0
Proceeds from issuance of common stock, net of direct costs
0 0
Proceeds from short-term convertible debt
0 4,375
Net cash provided by financing activities
0 4,375
Net decrease in cash and cash equivalents
-3,978 -5,140
Cash and cash equivalents at beginning of period
13,985 -
Cash and cash equivalents at end of period
4,867 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

FibroBiologics, Inc. (FBLG)

FibroBiologics, Inc. (FBLG)